[Translation] A multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial evaluating the efficacy and safety of CAN008 in combination with temozolomide in patients with newly diagnosed glioblastoma during and after radiation therapy
评价CAN008与替莫唑胺联合用药在放射治疗期间以及结束后治疗新诊断的胶质母细胞瘤患者的临床有效性,探索生物标记物对胶质母细胞瘤的预测和预后价值
[Translation] To evaluate the clinical efficacy of CAN008 in combination with temozolomide in the treatment of newly diagnosed glioblastoma patients during and after radiotherapy, and to explore the predictive and prognostic value of biomarkers for glioblastoma